RVXoldtimer... To your first comment, I never said you did. What I am saying is that RVX should not be setting the price by what is offered to them by the likes of Pfizer to use your example, then offering it to HL, if that is what you're saying. RVX needs to set their own price tag with the help of professionals in that line of business, such as Rothchild & Co. Perhaps this is why they brought them in the picture. Other than that we're pretty much in agreement. But one needs to look at the fine print of the ROFR.

However, I would not count HL USA out totally. Not yet anyway. As CD said they have a lot at stake. And contrary to what fouremm said, Shanzan Hepalink is not only in it to capitalize on the share price ( as healthy as they might be) they want to boost their manufacturing base and expand their existing distribution infrastructure to push Apabetalone to market in every which way. There are various ways to come up with the cash and to manufacture a drug if and when the situation warrants it. I can't see anyone parting with $8M if they have no serious interest, although the reason stated by fouremm why HL offered a ROFR is a valid one, primarily their insurance policy so to speak, not to let the USA RVX license go cheap.

JMO...Koo